The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon
Abstract
BACKGROUND Updated WHO guidelines recommend a dolutegravir-based regimen as the preferred first-line treatment for HIV infection and low-dose efavirenz (400 mg) as an alternative. We aimed to report the non-inferior efficacy of dolutegravir compared with efavirenz 400 mg at week 96. METHODS We did a multicentre, randomised, open label, phase 3 trial in in three hospitals in Yaoundé, Cameroon, in HIV-1 infected antiretroviral-naive adults with an HIV RNA viral load of greater than 1000 copies per mL to compare dolutegravir 50 mg with efavirenz 400 mg (reference treatment), both combined with lamivudine and tenofovir disoproxil fumarate. The primary endpoint was the proportion with a viral load of less than 50 copies per mL at week 48 (10% non-inferiority margin). The study is registered with ClinicalTrials.gov, NCT02777229 and is ongoing. FINDINGS Between July, 2016, and August, 2019, of 820 patients assessed, 613 were randomly assigned to receive at least one dose of study medication, with 310 in the dolutegravir group and 303 in the efavirenz 400 mg group. At week 96 in the intention-to-treat analysis, 229 (74%) of 310 patients receiving dolutegravir and 219 (72%) of 303 patients receiving efavirenz, achieved plasma HIV-1 RNA less than 50 copies per mL (difference 1·6%, 95% CI -5·4 to 8·6; p=0.66). Viral load suppression was reached significantly more rapidly in the dolutegravir group (p<0·001). Virological failure (>1000 copies per mL) was observed in 27 patients (eight in the dolutegravir group, among which, three women switched to efavirenz 600 mg because of the dolutegravir teratogeneicity signal, and 19 in the efavirenz 400 mg group). No acquired resistance mutations to dolutegravir were observed against 17 mutations to efavirenz with or without mutations to lamivudine and tenofovir disoproxil fumarate among the 19 efavirenz 400 mg participants with virological failure. Weight gain was greater in the dolutegravir group (median weight gain, 5·0 kg in the dolutegravir group and 3·0 kg in the efavirenz 400 mg group, p<0·001, and incidence of obesity, 22% in the dolutegravir group and 16% in the efavirenz 400 mg group, p=0·043). The incidence of new WHO HIV-related stage 3 and 4 events was similar in each group (12 [4%] in each group). The two groups had similar rates of serious adverse events (28 [9%] of 310 in the dolutegravir group and 21 [7%] of 303 in the efavirenz 400 mg group). 18 deaths were observed during the 96-week follow-up (eight in the dolutegravir group and ten in the efavirenz 400 mg group). INTERPRETATION The non-inferior efficacy of the dolutegravir-based regimen and non-emergence of dolutegravir resistance at 96 weeks supports its use as a first-line regimen for antiretroviral-naive adults with HIV-1 infection. Viral load suppression was reached more quickly in the dolutegravir group and weight gain was significantly higher. FUNDING UNITAID and the French National Agency for AIDS Research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cited by
Matthews, G., Jacoby, S., Borok, M., Eriobu, N., Kaplan, R., Kumarasamy, N., Bennet, J. A., Avihingsanon, A., Chetchotisakd, P., Wagner Cardoso, S., et al. (2024) · The Lancet HIV · doi:10.1016/s2352-3018(24)00089-4 · Cited by 31
Metadata
- Authors
- Calmy, A., Tovar Sanchez, T., Kouanfack, C., Mpoudi-Etame, M., Leroy, S., Perrineau, S., Lantche Wandji, M., Tetsa Tata, D., Omgba Bassega, P., Abong Bwenda, T., Varloteaux, M., Tongo, M., Mpoudi-Ngolé, E., Montoyo, A., Mercier, N., LeMoing, V., Peeters, M., Reynes, J., Delaporte, E., Calmy, A., Tovar Sanchez, T., Kouanfack, C., Mpoudi-Etame, M., Leroy, S., Perrineau, S., Lantche-Wandji, M., Tetsa-Tata, D., Omgba-Bassega, P., Abong-Bwenda, T., Varloteaux, M., Tongo, M., Mpoudi-Ngolé, E., Montoyo, A., Mercier, N., LeMoing, V, Peeters, M., Reynes, J., Delaporte, E., Ayouba, A., Agholeng, A., Butel, C., Cournil, A., Eymard-Duvernay, S., Granouillac, B., Izard, S., Lacroix, A., Serrano, L., Vidal, N., Fouda, P., Mougnoutou, R., Olinga, J., Omgba, V, Tchokonte-Ngandé, S., Ymele, B., Epoupa-Mpacko, C., Fotso, M., Moukoko, R., Nké, T., Akamba, A., Lekelem, S., Tongo-Fotack, S., Ngono, S., Tanga, M., Ebong, E., Edoul-Mbesse, G., Tongo, M., Ciaffi, L., Koulla-Shiro, S., Manirakiza, G., Mimbé, E., Boyer, S., Bousmah, M., Maradan, G., Nishimwe, M., Spire, B., Lê, M., Peytavin, G., Diallo, A., Fournier, I., Rekacewicz, C., & Perez Casas, C.
- Venue
- The Lancet HIV
- Publisher
- Elsevier BV
- Published
- 2020-10
- Volume
- 7
- Issue
- 10
- Pages
- e677-e687
- ISSN
- 2352-3018 (ISSN-L)
- OpenAlex
- W3089405003
- Cited by
- 161
- References
- 1
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. https://app.cochat.ai/papers/10.1016/s2352-3018(20)30238-1
- The paper
- Calmy, A., Tovar Sanchez, T., Kouanfack, C., Mpoudi-Etame, M., Leroy, S., Perrineau, S., Lantche Wandji, M., Tetsa Tata, D., Omgba Bassega, P., Abong Bwenda, T., Varloteaux, M., Tongo, M., Mpoudi-Ngolé, E., Montoyo, A., Mercier, N., LeMoing, V., Peeters, M., Reynes, J., Delaporte, E., . . . Perez Casas, C. (2020). Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon. The Lancet HIV. https://doi.org/10.1016/s2352-3018(20)30238-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.